Zogenix Inc (ZGNX)

HEALTH CARE: PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS

5959 HORTON STREET, SUITE 500 EMERYVILLE, CA 94608

Zogenix, Inc., a pharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system disorders and pain.

Data as of 2020-07-04
Market Cap1.615 Billion Shares Outstanding55.341 Million Avg 30-day Volume1.404 Million
P/E Ratio Dividend Yield EPS-9.38
Price/Sales421.994 Price cash flow ratio Price free cash flow ratio-13.0
Book Value8.14 Price to Tangible Book4.73 Alpha0.03
Short Interest Ratio % Short Interest to Float R-squared0.055744
BETA1.72226 52-week High/Low57.22 / 16.65 Stddev0.310637
View SEC Filings from ZGNX instead.
Q1 2020 All Institutions Hedge Funds 1
Filers who had this stock in their top 10: 5 4 (0.26%)
13F Filers holding this stock: 163 60 (3.93%)
Aggregate 13F shares on 03/31/2020: 62.701 Million 35.302 Million
Aggregate 13F shares on 12/31/2019: 48.7 Million 31.277 Million
Percent change: 28.75% 12.87%
Funds creating new positions: 42 17
Funds Adding to an existing position: 65 29
Funds closing out their position: 42 17
Funds reducing their position: 36 9
1 hedge funds as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding ZGNX (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding ZGNX BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

1 Thousand total shares from 1 transactions

Open Market Sells (S)

2.6 Thousand total shares from 1 transactions

Exercise Derivative Conversion (M)

50 Thousand total shares from 4 transactions

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

SAGROLIKAR ASHISH M EVP & CHIEF COMMERCIAL OFFICER

  • Officer
9,118 2020-07-02 4

FARR STEPHEN J PRESIDENT AND CEO

  • Officer
  • Director
79,720 2020-06-25 7

GALER BRADLEY S. EVP/CHIEF MEDICAL OFFICER

  • Officer
17,202 2020-06-25 4

FARFEL GAIL M EVP/CHIEF DEVELOPMENT OFFICER

  • Officer
11,179 2020-06-25 5

RHOADS ANN D

  • Director
4,000 2020-06-23 0

BREITMEYER JAMES B

  • Director
0 2020-06-23 3

PERCEPTIVE ADVISORS LLC

PERCEPTIVE LIFE SCIENCES MASTER FUND LTD

EDELMAN JOSEPH

  • 10% Owner
8,476,496 2020-06-22 0

HALAK BRIAN K

  • Director
0 2020-06-18 0

KAMDAR KIM P.

  • Director
  • 10% Owner
9,287 2020-06-12 0

TREU JESSE I

  • Director
0 2020-06-09 0

BLAIR JAMES C

  • Director
0 2020-06-04 0

BOCK LOUIS C

  • Director
0 2020-05-29 1

WIGGINS MARK C

  • Director
0 2020-05-29 3

MAST ERLE T

  • Director
0 2020-05-29 1

GARNER CAM L

  • Director
0 2020-05-29 2

TANNENBAUM RENEE P

  • Director
0 2020-05-29 1

VITULLO NICOLE

  • Director
19,392 2020-05-28 0

MITCHELL SHAWNTE EVP, GC AND SECRETARY

  • Officer
0 2020-04-20 2

SMITH MICHAEL P EVP, CFO, TREASURER & SEC.

  • Officer
3,199 2020-03-15 5

DOVEY BRIAN H

  • Director
0 2019-11-11 0

HAWLEY ROGER

  • Director
0 2019-06-13 0

WHEELER KURT

  • Director
0 2019-01-22 0

MINOCHERHOMJEE ARDA PHD

  • Director
0 2018-08-13 0

DARCIS THIERRY J.P. EVP / GENERAL MANAGER, EUROPE

  • Officer
0 2017-03-14 0

SHIVELY RICHARD SCOTT SVP & CHIEF COMMERCIAL OFFICER

  • Officer
4,290 2016-04-02 0

SCHOEMAKER KATHLEEN K

  • 10% Owner
No longer subject to file 2014-03-19 0

DP VII ASSOCIATES LP

  • 10% Owner
No longer subject to file 2014-03-19 0

DOMAIN PARTERS VII L P

  • 10% Owner
No longer subject to file 2014-03-19 0

DOMAIN ASSOCIATES

  • 10% Owner
No longer subject to file 2014-03-19 0

DOMAIN PARTNERS VI, L.P.

  • 10% Owner
No longer subject to file 2014-03-19 0

DP VI ASSOCIATES, L.P.

  • 10% Owner
No longer subject to file 2014-03-19 0

CLARUS LIFESCIENCES I, L.P.

CLARUS VENTURES I MANAGEMENT, L.P.

CLARUS VENTURES I, LLC

GALAKATOS NICHOLAS

HENNER DENNIS

LIPTAK ROBERT

SIMON NICHOLAS

STEINMETZ MICHAEL

WHEELER KURT

  • 10% Owner
  • GENERAL PARTNERGP CLARUS VENTURES I MNGMT.MANAGING DIR. OF GPMANAGING DIR. OF GPMANAGING DIR. OF GPMANAGING DIR. OF GPMANAGING DIR. OF GPMANAGING DIR. OF GP
No longer subject to file 2013-09-03 0

ROBINSON CYNTHIA Y CHIEF DEVELOPMENT OFFICER

  • Officer
0 2013-03-15 0

SCALE VENTURE PARTNERS II, LP

SCALE VENTURE MANAGEMENT II, LLC

MITCHELL KATE

O'DRISCOLL RORY

WIENBAR SHARON L

  • FORMER 10% HOLDERFORMER 10% HOLDERFORMER 10% HOLDERFORMER 10% HOLDERFORMER 10% HOLDER
No longer subject to file 2011-09-21 0

CLARUS LIFESCIENCES I, L.P.

CLARUS VENTURES I, LLC

CLARUS VENTURES I MANAGEMENT, L.P.

LIPTAK ROBERT

SIMON NICHOLAS

HENNER DENNIS

GALAKATOS NICHOLAS

STEINMETZ MICHAEL

  • 10% Owner
5,982,439 2010-11-29 0

THOMAS MCNERNEY & PARTNERS LP

THOMAS, MCNERNEY & PARTNERS, LLC

TMP NOMINEE, LLC

TMP ASSOCIATES LP

THOMAS, MCNERNEY & PARTNERS II L.P.

THOMAS, MCNERNEY & PARTNERS II, LLC

TMP NOMINEE II, LLC

TMP ASSOCIATES II LP

THOMAS JAMES E

MCNERNEY PETE

  • SEE FOOTNOTE (10)SEE FOOTNOTE (10)SEE FOOTNOTE (10)SEE FOOTNOTE (10)SEE FOOTNOTE (10)SEE FOOTNOTE (10)SEE FOOTNOTE (10)SEE FOOTNOTE (10)SEE FOOTNOTE (10)SEE FOOTNOTE (10)
No longer subject to file 2010-11-29 0

SCALE VENTURE PARTNERS II, LP

SCALE VENTURE MANAGEMENT II, LLC

BROOKS MARK J

MITCHELL KATE

O'DRISCOLL RORY

WIENBAR SHARON L

  • 10% Owner
4,071,546 2010-11-29 0

HAAS KEN

  • Director
2,335,218 2010-11-29 0

CHICAGO GROWTH PARTNERS II L P

CHICAGO GROWTH MANAGEMENT II, LLC

CHICAGO GROWTH MANAGEMENT II, LP

  • SEE REMARKSSEE REMARKSSEE REMARKS
No longer subject to file 2010-11-29 0

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5

SAGROLIKAR ASHISH M - Officer EVP & CHIEF COMMERCIAL OFFICER

2020-07-02 M 3,750 a 10,232 9,118.00 direct

SAGROLIKAR ASHISH M - Officer EVP & CHIEF COMMERCIAL OFFICER

2020-07-02 M 3,750 d 7,500 9,118.00 direct

SAGROLIKAR ASHISH M - Officer EVP & CHIEF COMMERCIAL OFFICER

2020-07-02 F 1,114 $29.19 d 9,118 9,118.00 direct

GALER BRADLEY S. - Officer EVP/CHIEF MEDICAL OFFICER

2020-06-25 M 10,000 a 20,015 17,202.00 direct

FARR STEPHEN J - Director - Officer PRESIDENT AND CEO

2020-06-25 F 13,635 $28.12 d 79,720 79,720.00 direct

FARFEL GAIL M - Officer EVP/CHIEF DEVELOPMENT OFFICER

2020-06-25 F 3,044 d 11,179 11,179.00 direct

GALER BRADLEY S. - Officer EVP/CHIEF MEDICAL OFFICER

2020-06-25 M 10,000 d 0 17,202.00 direct

FARR STEPHEN J - Director - Officer PRESIDENT AND CEO

2020-06-25 M 27,500 a 93,355 79,720.00 direct

FARFEL GAIL M - Officer EVP/CHIEF DEVELOPMENT OFFICER

2020-06-25 M 8,750 a 14,223 11,179.00 direct

GALER BRADLEY S. - Officer EVP/CHIEF MEDICAL OFFICER

2020-06-25 F 2,813 $28.12 d 17,202 17,202.00 direct

FARR STEPHEN J - Director - Officer PRESIDENT AND CEO

2020-06-25 M 27,500 d 0 79,720.00 direct

FARFEL GAIL M - Officer EVP/CHIEF DEVELOPMENT OFFICER

2020-06-25 M 8,750 d 0 11,179.00 direct

TANNENBAUM RENEE P - Director

2020-05-29 A 13,000 a 13,000 0.00 direct

GARNER CAM L - Director

2020-05-29 A 13,000 a 13,000 0.00 direct

BOCK LOUIS C - Director

2020-05-29 A 13,000 a 13,000 0.00 direct

MAST ERLE T - Director

2020-05-29 A 13,000 a 13,000 0.00 direct

BREITMEYER JAMES B - Director

2020-05-29 A 13,000 a 13,000 0.00 direct

WIGGINS MARK C - Director

2020-05-29 A 13,000 a 13,000 0.00 direct

FARFEL GAIL M - Officer EVP/CHIEF DEVELOPMENT OFFICER

2020-05-12 S 2,573 $28.21 d 5,048 5,048.00 direct yes

SAGROLIKAR ASHISH M - Officer EVP & CHIEF COMMERCIAL OFFICER

2020-05-08 P 1,000 $25.45 a 5,913 5,913.00 direct
Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

Elevate your investments